Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps for ADHD? new study tests iTBS in children

NCT ID NCT07182344

Symptom relief Sponsor: Neurolab Plus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a non-invasive brain stimulation technique called iTBS can improve attention and self-control in children aged 6 to 12 with ADHD. Over two weeks, 40 children will receive either real or sham stimulation, and researchers will measure changes in attention using computer tasks, brain scans, and genetic tests. The goal is to see if iTBS helps and who might benefit most.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intermittent theta burst stimulation (iTBS) delivered via a device to the brain
What this could lead to
If it works, this could point toward a non-drug treatment to help children with ADHD improve attention and self-control.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to all children with ADHD. The treatment is short-term and may not produce lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 6-12 years at the time of enrollment. * Clinical diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), any presentation type, confirmed using the Vanderbilt ADHD Diagnostic Parent Rating Scale and clinical interview. * Intelligence quotient (IQ) ≥ 70 as measured by the General Ability Index (GAI) from the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V). * Ability to understand and follow instructions for the Attention Network Test (ANT) and stimulation procedure. * Stable medication regimen for ADHD (if any) for at least 4 weeks before the start of the study. * Written informed consent from a parent or legal guardian, and assent from the child when appropriate. Exclusion Criteria: * History of epilepsy, seizures, or abnormal EEG suggestive of seizure risk. * Presence of metal implants, devices, or foreign bodies in or near the head (except dental fillings) that are contraindicated for TMS or MRI. * Serious neurological disorders other than ADHD (e.g., cerebral palsy, brain injury, neurodegenerative disease). * Severe psychiatric disorders requiring hospitalization or urgent intervention. * Current or past history of significant head trauma with loss of consciousness \> 5 minutes. * Uncorrected hearing or vision problems that could interfere with task performance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD - attention deficit disorder with hyperactivity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder neurodevelopmental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD - attention deficit disorder with hyperactivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Neurolab Plus

    Almaty, 050000, Kazakhstan

  • Non-profit joint-stock company "Al-Farabi Kazakh National University"

    Almaty, 050040, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.